- Home
- TBBB vs MRUS Comparison
TBBB vs MRUS Comparison
Compare TBBB & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBB
- MRUS
- Stock Information
- Founded
- TBBB 2004
- MRUS 2003
- Country
- TBBB Mexico
- MRUS Netherlands
- Employees
- TBBB N/A
- MRUS N/A
- Industry
- TBBB
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- TBBB
- MRUS Health Care
- Exchange
- TBBB NYSE
- MRUS Nasdaq
- Market Cap
- TBBB 3.5B
- MRUS 4.1B
- IPO Year
- TBBB 2024
- MRUS 2016
- Fundamental
- Price
- TBBB $26.37
- MRUS $53.11
- Analyst Decision
- TBBB Hold
- MRUS Strong Buy
- Analyst Count
- TBBB 5
- MRUS 12
- Target Price
- TBBB $33.40
- MRUS $87.92
- AVG Volume (30 Days)
- TBBB 463.9K
- MRUS 2.0M
- Earning Date
- TBBB 05-07-2025
- MRUS 07-31-2025
- Dividend Yield
- TBBB N/A
- MRUS N/A
- EPS Growth
- TBBB N/A
- MRUS N/A
- EPS
- TBBB 0.16
- MRUS N/A
- Revenue
- TBBB $3,027,881,094.00
- MRUS $54,732,000.00
- Revenue This Year
- TBBB $33.45
- MRUS $75.57
- Revenue Next Year
- TBBB $27.61
- MRUS $31.84
- P/E Ratio
- TBBB $161.18
- MRUS N/A
- Revenue Growth
- TBBB 31.48
- MRUS 42.77
- 52 Week Low
- TBBB $21.72
- MRUS $33.19
- 52 Week High
- TBBB $35.22
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- TBBB N/A
- MRUS 53.18
- Support Level
- TBBB N/A
- MRUS $52.41
- Resistance Level
- TBBB N/A
- MRUS $54.59
- Average True Range (ATR)
- TBBB 0.00
- MRUS 2.15
- MACD
- TBBB 0.00
- MRUS -0.77
- Stochastic Oscillator
- TBBB 0.00
- MRUS 7.62
About TBBB BBB FOODS INC
BBB Foods Inc is a company offering a grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B, Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.